Guillermo Villacampa

A <scp>RAD</scp> 51 assay feasible in routine tumor samples calls <scp>PARP</scp> inhibitor response beyond <scp>BRCA</scp> mutation

Marta Castroviejo‐Bermejo, Cristina Cruz, Alba Llop‐Guevara et al. · EMBO Molecular Medicine · 2018 · 263 citations · Full text

Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer

Rodrigo Dienstmann, Guillermo Villacampa, Anita Sveen et al. · Annals of Oncology · 2019 · 259 citations · Full text

Minimizing acquisition-related radiomics variability by image resampling and batch effect correction to allow for large-scale data analysis

Marta Ligero, Olivia Jordi-Ollero, Kinga Bernatowicz et al. · European Radiology · 2020 · 198 citations · Full text

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Ana Oaknin, Laurence Gladieff, Jerónimo Martínez-García et al. · The Lancet · 2023 · 175 citations

Oncology, Cervical Cancer, Metronomic Therapy +6

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial

Sara M. Tolaney, Paolo Tarantino, Noah Graham et al. · The Lancet Oncology · 2023 · 151 citations

Breast Oncology, Oncology, Breast Cancer +6